Bidding Falls, Domestic Bisphenol A Market Advances Steadily
Today, the domestic bisphenol A market is stable and excessive. In the morning, the price of Lihua Yiweiyuan was raised by 200 yuan to 11,700 CNY/ton. However, due to the poor demand side, it habitually opened as before at the beginning of the week, and the wait-and-see mood in the market was still heavier.
The raw material side has pulled back, but the overall decline is not large, and the cost side is difficult to support. Then on Monday, a petrochemical company in East China auctioned, and the delivery price of high-quality products was 11,300 CNY/ton, which was 250 CNY/ton lower than last week's auction. Recently, the adjustment of dual raw materials has been flat
, the downstream epoxy resin fluctuates in a narrow range
, the business agency expects short-term market stability
, the upward lack of positive support from the demand side of the industrial chain.
You May Interested In
2026-10-09
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Japan Extends Bisphenol A Anti-Dumping Probe, Prolonging Uncertainty for Korean and Taiwanese Suppliers
-
Raw Materials Strengthen; PC Prices Show Volatility with a Rise at Late January
-
Pre-holiday inventory buildup sluggish; PCs operate at low levels through late December
-
Market Trends and Outlook for Key Chemicals in China
-
Chemical Market Update: BPA and Epoxy Resin Trends in Focus
-
Market Insights: Recent Trends in China's Chemical Industry
-
Recent Trends in Chemical Markets: Bisphenol A, Phenol, Acetone, Epichlorohydrin, and Epoxy Resin
-
Analysis and Outlook of the Domestic Chemical Market
-
Chemical Raw Materials Market Weekly Report: Comprehensive Analysis of Bisphenol A and Epichlorohydrin Market Trends
-
The European Union has reassessed the public health risks of bisphenol A in food
Recommend Reading
-
![BASF, Covestro, Huntsman Raise MDI Prices in North America Amid Global Supply Crunch]()
BASF, Covestro, Huntsman Raise MDI Prices in North America Amid Global Supply Crunch
-
![Growing Pains, But the Roots Are Strong: Corteva Narrows Losses Amid Sales Surge in Q3 2025]()
Growing Pains, But the Roots Are Strong: Corteva Narrows Losses Amid Sales Surge in Q3 2025
-
![From the Brink to the Bend: Bayer’s Q3 2025 Shows Dramatic Loss Reduction—but Crop Science Still Bleeds]()
From the Brink to the Bend: Bayer’s Q3 2025 Shows Dramatic Loss Reduction—but Crop Science Still Bleeds
-
![Profit Soars While Sales Dip: Syngenta Group Defies Headwinds with 28% EBITDA Surge in Q3 2025]()
Profit Soars While Sales Dip: Syngenta Group Defies Headwinds with 28% EBITDA Surge in Q3 2025
-
![Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera]()
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
![U.S. and China Open New High-Level Trade Talks on Tariffs, Critical Minerals and Pharma Investment]()
U.S. and China Open New High-Level Trade Talks on Tariffs, Critical Minerals and Pharma Investment
-
![China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot]()
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
-
![Business Society September 21, 2026 Phenol Trend Analysis: Weakly Tending]()
Business Society September 21, 2026 Phenol Trend Analysis: Weakly Tending
-
![关于将4-amino-1-boc-piperidine、tert-buty 4-aminopiperidine-1-carboxylate产品列入《ECHEMI平台禁限售商品目录》的公告 Announcement on Including 4-amino-1-boc-piperidine and tert-buty 4-aminopiperidine-1-carboxylate in the Announcement on the List of Prohibited Sales of Prohibited and Controlled Items on ECHEMI]()
关于将4-amino-1-boc-piperidine、tert-buty 4-aminopiperidine-1-carboxylate产品列入《ECHEMI平台禁限售商品目录》的公告 Announcement on Including 4-amino-1-boc-piperidine and tert-buty 4-aminopiperidine-1-carboxylate in the Announcement on the List of Prohibited Sales of Prohibited and Controlled Items on ECHEMI
-
![Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger]()
Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger
